MORPHINE-6-β-GLUCURONIDE is a metabolite of morphine with potent opioid agonist activity. 1
It is eliminated by the kidney, and therefore, accumulates in patients suffering from renal failure potentially causing long lasting opioid effects. 2
Morphine-6-glucuronide crosses the blood–brain barrier much slower and to a much smaller extent than morphine. 3
The slow transfer of morphine-6-glucuronide from the blood into the brain probably prevents building up brain levels sufficiently high to cause intoxication in patients with normal renal function. It also prevents morphine-6-glucuronide from exerting central nervous opioid action after its short-term administration. 4
However, we describe a case that illustrates the clinical significance of the slow transit of morphine-6-glucuronide to and from the effect site (brain) in a patient suffering from renal failure.
A 22-yr-old man with Goodpasture syndrome resulting in end-stage renal disease and severe arterial hypertension underwent bilateral nephrectomy. He received 40 and 30 mg of morphine, respectively, as the sole analgesic at the beginning and at the end of the 3.5 h surgery (intravenous bolus injections). Postoperative patient-controlled analgesia using morphine was installed. The patient indicated mild pain at rest and severe pain when moving and self-administered 36 mg of intravenous morphine during the first 18 h after surgery and another 4 mg during the following 13 h. His morphine demand during the first 18 h after surgery was higher than approved by the patient-controlled analgesia setting. The patient became unconscious 31 h after surgery and remained in that state for 45 h. This time course was also reflected by the results of vigilance tests administered in the postoperative period (Galveston orientation and amnesia test, 5
digital span test assessing how many ciphers can be repeated correctly, and reaction time to a visual stimulus). Despite profound unconsciousness respiratory depression was clinically not prominent. As part of a routine managing unconscious patients, 2–4 l · min-1
of oxygen by nasal probe was administered. The hemoglobin oxygen saturation remained above 93% except for one occasion 66 h after the end of surgery (resolved after suctioning of intratracheal secretion). The patient underwent hemodialysis 45 h, 88 h, and 162 h after surgery. He was unconscious during the first hemodialysis and remained in that state 34 h thereafter.
Blood samples were drawn in the pre- and postoperative period to assay for plasma concentrations of morphine and its glucuronide metabolites using high performance liquid chromatography. 6
When the patient became unconscious 31 h after surgery, the morphine plasma concentration had been below the lower limit of quantification of 25 ng/ml for more than 26 h. 6
On the other hand, morphine-6-glucuronide concentrations had already been close to their maximum for 26 h. The hemodialysis starting 45 h after surgery almost completely cleared morphine-6-glucuronide from plasma. However, the patient did not regain consciousness until 34 h after hemodialysis (see fig. 1
The equilibration half-life of morphine-6-glucuronide between plasma and the brain was estimated using a nonparametric approach. 7
It was consistently long with 36 h, 58 h, or 161 h when the Galveston orientation and amnesia test, reaction time, or digital span test data were used for the calculation, respectively.
The present observation shows that in the setting of renal insufficiency severe opioid side effects can occur many hours after morphine plasma concentrations have peaked and morphine-6-glucuronide concentrations have reached a plateau in plasma. These side effects are most likely mediated by morphine-6-glucuronide and not by morphine or morphine-3-glucoronide. The main morphine metabolite morphine-3-glucuronide does not exert depressant effects in the central nervous system. 8
Morphine itself equilibrates too quickly from blood into the brain to account for observed delay of many hours between the plasma concentration versus
time profile and the effect versus
time profile, respectively. Despite two large intravenous doses of morphine during surgery the patient experienced postoperative pain and continued to self-administer morphine by patient-controlled analgesia. At this time the high plasma concentrations of morphine-6-glucuronide did not seem to result in clinically relevant analgesia. However, with a delay of many hours similar plasma concentrations of morphine-6-glucuronide resulted in toxic side effects, i.e.
, the patient became unconscious. As the slow transfer between plasma and effect compartment is the reason for the delayed appearance of opioid side effects, it is also likely to be the reason why the patient remained unconscious for a long period after morphine-6-glucornide had disappeared from plasma. Despite its elimination from plasma, it was probably still present at the effect site at high enough concentrations to maintain clinical opioid effects. Morphine effects probably having ceased before morphine-6-glucuronide effects becoming clinically relevant seems to explain why the patient continued to self-administer morphine by patient-controlled analgesia.
Despite profound unconsciousness the patient suffered little from respiratory depression. This is compatible with reports suggesting that morphine-6-glucuronide causes less respiratory depression than morphine. 9
However, other investigators attributed profound respiratory depression to morphine-6-glucuronide rather than to morphine. 2,10,11
Despite inconsistent reports on the relative potency of morphine and morphine-6-glucuronide in regard to respiratory depression, it is widely accepted that morphine and morphine-6-glucuronide exert differential pharmacodynamic activity at the receptor level. Both act mainly by stimulating μ-opioid receptor as recently confirmed by their drastically attenuated activity in μ-opioid-receptor knockout mice. 12
Morphine and morphine-6-glucuronide bind to the μ-opioid receptor with comparable affinity. 1
This contrasts with an up to 650-fold higher analgesic potency of morphine-6-glucuronide relative to morphine. 1
This discrepancy between functional and binding activity led to the hypothesis that morphine and morphine-6-glucuronide have differential binding affinity to variants of the μ-opioid receptor.
A single μ-receptor gene, MOR-1, has been identified. 13
However, antisense mapping studies revealed that the MOR-1
gene contains at least nine exons, and six distinct MOR-1
receptors have so far been described. 14
Interestingly, different exons of the MOR-1
gene seem to code receptor variants involved in either morphine or morphine-6-glucuronide antinociception. 15
When transcription of exon 1 of the MOR-1 receptor gene was inhibited by a specific antisense oligodeoxynucleotide, morphine antinocciception in rats was blocked but morphine-6-glucuronide antinociception remained unchanged. 15,16
In contrast, targeting exons 2 and 3 with antisense oligodeoxynucleotides decreased morphine-6-glucuronide but not morphine antinociception. 15,16
The importance of exon 2 but not exon 1 for morphine-6-glucuronide mediated antinociception was also demonstrated in knockout mice. 17
These results have led to the proposal that a distinct morphine-6-glucuronide receptor exists as a splice variant of the MOR-1
The fact that different splicing variants of the MOR-1
gene seem to mediate either morphine or morphine-6-glucuronide antinociceptive effect raises the question whether this is also true for other than antinociceptive effects. So far, there is evidence that exon 4, but not exons 1 to 3 are involved in coding the receptor mediating inhibitory effects on gastrointestinal transit. There is currently no information about the contribution of different MOR-1
splice variants for mediating respiratory depression. However, in light of outlined findings one may speculate that the patient reported here has suffered from profound unconsciousness but not significant respiratory depression because of differential activity of morphine and morphine-6-glucuronide on receptors constituting different splice variants of the MOR-1 gene.
Monitoring of morphine plasma concentrations in the present clinical case would not have given any indication for upcoming severe opioid side effects. Even monitoring of morphine-6-glucuronide plasma concentrations would not necessarily have led to the conclusion of toxicity because morphine-6-glucuronide levels were high for a long time without clinical effects. Multiple dosing of morphine in patients prone to accumulate morphine-6-glucuronide is problematic and bears the risk of delayed severe intoxication since the effects of morphine-6-glucuronide will not become apparent for many hours. Replacement of morphine by opioids with pharmacokinetics that do not depend on renal elimination seems wise and drugs like tilidine, buprenorphine, or sufentanil, should be considered.
1. Paul D, Standifer KM, Inturrisi CE, Pasternak GW: Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251:477–83
2. Hasselström J, Berg U, Lofgren A, Säwe J: Long lasting respiratory depression induced by morphine-6- glucuronide? Br J Clin Pharmacol 1989; 27:515–8
3. Bickel U, Schumacher O, Kang YS, Voigt K: Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat. J Pharmacol Exp Ther 1996; 278:107–13
4. Lötsch J, Kobal G, Stockmann A, Brune K, Geisslinger G: Lack of analgesic activity of morphine-6-glucuronide after short-term intravenous administration in healthy volunteers. A nesthesiology 1997; 87:1348–58
5. Levin HS, O’Donnell VM, Grossman RG: The Galveston Orientation and Amnesia Test. A practical scale to assess cognition after head injury. J Nerv Ment Dis 1979; 167:675–84
6. Bourquin D, Lehmann T, Hammig R, Buhrer M, Brenneisen R: High-performance liquid chromatographic monitoring of intravenously administered diacetylmorphine and morphine and their metabolites in human plasma. J Chromatogr B 1997; 694:233–8
7. Unadkat JD, Bartha F, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models. Clin Pharmacol Ther 1986; 40:86–93
8. Gardmark M, Karlsson MO, Jonsson F, Hammarlund-Udenaes M: Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling. J Pharm Sci 1998; 87:813–20
9. Thompson PI, Joel SP, John L, Wedzicha JA, MacLean M, Slevin ML: Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40:145–52
10. Grace D, Fee JP: A comparison of intrathecal morphine-6-glucuronide and intrathecal morphine sulfate as analgesics for total hip replacement. Anesth Analg 1996; 83:1055–9
11. Gong QL, Hedner T, Hedner J, Bjorkman R, Nordberg G: Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. Eur J Pharmacol 1991; 193:47–56
12. Loh HH, Liu HC, Cavalli A, Yang W, Chen YF, Wei LN: mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res 1998; 54:321–6
13. Min BH, Augustin LB, Felsheim RF, Fuchs JA, Loh HH: Genomic structure analysis of promoter sequence of a mouse mu opioid receptor gene. Proc Natl Acad Sci USA 1994; 91:9081–5
14. Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, Pasternak GW: Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 1999; 56:396–403
15. Rossi GC, Pan YX, Brown GP, Pasternak GW: Antisense mapping the MOR-1 opioid receptor: evidence for alternative splicing and a novel morphine-6 beta-glucuronide receptor. FEBS Lett 1995; 369:192–6
16. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, Pasternak GW: Antisense mapping of MOR-1 in rats: Distinguishing between morphine and morphine-6beta-glucuronide antinociception. J Pharmacol Exp Ther 1997; 281:109–14
17. Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, Chang A, Czick ME, Unterwald EM, Pasternak GW, Pintar JE: Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 1999; 2:151-6
© 2000 American Society of Anesthesiologists, Inc.